Clinical trials: Cytomegalovirus Prophylaxis
Cytomegalovirus (CMV), Kidney Transplant; Complications
Kidney Transplant Preemptive Therapy or Prophylaxis for CMV Prevention in D+R Recipients
This is a prospective, randomized multicenter trial of preemptive therapy (PET) vs. antiviral prophylaxis (AP) for prevention of cytomegalovirus (CMV) disease in adult D+R- kidney transplant recipients (KTR).
- Conditions
- Cytomegalovirus (CMV), Kidney Transplant; Complications, Kidney Diseases
- Trial name
- KPoP (NCT06798909)
- Testing
- Valganciclovir (Pre-emptive CMV Therapy), Valganciclovir CMV Prophylaxis
- Where
- 8 sites in United States
- Volunteers
- 360 people
- Sponsor
- University of California, San Francisco
Kidney Transplant
Efficacy and Safety of Leymovir Versus Valganciclovir in Prevention of Cytomegalovirus Infection and Cytomegalovirus Disease in Chinese Kidney Transplant Recipients
the existing anti-CMV drugs mainly include valganciclovir, ganciclovir and foscarnet sodium, all of which act on DNA polymerase (pUL54), making them prone to cross resistance.
- Trial name
- CAPS01 (NCT07266467)
- Testing
- Letermovir, Valganciclovir
- Where
- China
- Volunteers
- 290 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
CMV Infection
Reducing Post-Letermovir CMV Infection: Efficacy of an Immune-Reconstitution-Based Scoring System to Guide Prophylaxis Duration
With the increasing use of letermovir and considering that haploidentical hematopoietic stem cell transplantation (haplo-HSCT) predominates in China alongside a high CMV seroprevalence in the population, multiple domestic centers…
- Trial name
- NCT07443501
- Volunteers
- 1,114 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Transplant Recipients With CMV Infection
A French Cohort of Transplant Recipients With CMV Infection : Risk Factors for Antiviral Resistance in the Prophylaxis Era.
Resistance to antivirals is a growing problem in transplantation.that may concerns up to 5% of patients treated for cytomegalovirus (CMV) syndrome or disease in recent per-protocol studies.
- Trial name
- ORPHAVIC (NCT02067169)
- Testing
- CMV Infection
- Where
- 38 sites in France
- Volunteers
- 408 people
- Sponsor
- University Hospital, Limoges
Hematopoietic/Lymphoid Cancer, Accelerated Phase Chronic Myelogenous Leukemia
Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant
RATIONALE: Infection prophylaxis and management may help prevent cytomegalovirus (CMV) infection caused by a stem cell transplant.
- Conditions
- Hematopoietic/Lymphoid Cancer, Accelerated Phase Chronic Myelogenous Leukemia, Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
- Trial name
- NCT01199562
- Testing
- infection prophylaxis and management, laboratory biomarker analysis, flow cytometry
- Where
- United States
- Volunteers
- 153 people
- Sponsor
- City of Hope Medical Center
Hematopoietic Stem Cell Transplantation, Cytomegalovirus Infections
Evaluation of CMV/EBV-CMI in Haploid HSCT
The purpose of this prospective, open-label, Single Arm, single-center study is to evaluate the cytomegalovirus and Epstein-Barr virus specific immune reestablishment for patients with hemopathy undergoingin prophylaxis for…
- Conditions
- Hematopoietic Stem Cell Transplantation, Cytomegalovirus Infections, Epstein-Barr Virus Infections
- Trial name
- NCT06554197
- Testing
- CMV/EBV-CMI
- Where
- China
- Volunteers
- 60 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Cytomegalovirus Infection
Extension of Letermovir (LET) From Day 100 to Day 200 Post-transplant for the Prevention of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant (HSCT) Participants (MK-8228-040)
The purpose of this study was to evaluate the safety and efficacy of letermovir (LET) versus placebo when cytomegalovirus (CMV) prophylaxis was extended from 100 days to 200 days post-transplant in CMV seropositive participants…
- Trial name
- NCT03930615
- Testing
- Letermovir
- Where
- 32 sites in United States, France and 4 more
- Volunteers
- 220 people
- Sponsor
- Merck Sharp & Dohme LLC
Cytomegalovirus Infections
Cytotoxic T-Lymphocytes for the Prophylaxis of Cytomegalovirus After Allogeneic Stem Cell Transplant
Patients have a type of blood cell cancer, other blood disease or a genetic disease for which they will receive a stem cell transplant.
- Trial name
- VICTA (NCT00078533)
- Testing
- CMV CTL infusion
- Where
- 2 sites in United States
- Volunteers
- 26 people
- Sponsor
- Baylor College of Medicine
CMV Viremia
Cytomegalovirus Prophylaxis With Letermovir in Heart Transplant Recipients
CMV infection is the most prevalent infection after heart transplantation (HTX), occurring in up to 40-60% of the recipients. It most frequently occurs within the first 6 months after transplantation and commonly presents as an…
- Trial name
- CYPHER-TXPilot (NCT05432778)
- Testing
- Letermovir Pill
- Where
- Slovenia
- Volunteers
- 90 people
- Sponsor
- University Medical Centre Ljubljana
DNA Virus Infection, Herpesviridae Infections
Prophylaxis With Ganciclovir Improves Graft Survival in Renal Allograft Recipients
Study Phase: IV Study Type: Open-label, multicenter, randomised clinical trial with two arms stratified for an intensified immunosuppressive regimen in patients at high risk for acute rejection.
- Conditions
- DNA Virus Infection, Herpesviridae Infections, Cytomegalovirus Infection
- Trial name
- NCT00373165
- Testing
- Ganciclovir
- Volunteers
- 150 people
- Sponsor
- Lower Saxony Center for Nephrology
Cytomegalovirus Congenital
Primary Prevention of Cytomegalovirus in Pregnancy: Addressing the Gaps (CMV GAP)
CMV is the most common congenital infection (an infection acquired before birth) in the UK. It is the leading non-genetic cause of sensorineural (inner ear) hearing loss and a common cause of neuro-disability.
- Trial name
- CMV GAP (NCT04879784)
- Testing
- No intervention
- Volunteers
- 6,000 people
- Sponsor
- University Hospital Southampton NHS Foundation Trust
Renal Transplant Recipients
The Strategy in the Prevention of Renal Post-transplant Cytomegalovirus Infection Among Chinese Population
This study evaluates the safety and availability of oral valganciclovir(VGC) at the does of 450mg daily begin within 10 days after renal transplantation, and till to Day 100 posttransplant.
- Trial name
- NCT02973464
- Testing
- Valganciclovir, Ganciclovir
- Where
- China
- Volunteers
- 450 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Kidney Transplant Infection
Randomized Clinical Trial, Open, Multicenter Parallel, no Suspension Inferiority Prophylactic Treatment With Valganciclovir in Kidney Transplant CMV-seropositive Cellular Immunity to Develop CD8 + CMV-specific Treatment After Induction Thymoglobulin.
Hypothesis: Valganciclovir prophylaxis can be discontinued before 3 months in CMV-seropositive renal transplant recipients receiving induction thymoglobulin when developing CMV-specific cellular immunity after transplantation.
- Trial name
- NCT03123627
- Testing
- New profilaxis, Profilaxis recommended
- Where
- Spain
- Volunteers
- 150 people
- Sponsor
- Maimónides Biomedical Research Institute of Córdoba
Cytomegalovirus Infections
Maribavir Versus Oral Ganciclovir For The Prevention of Cytomegalovirus (CMV) Disease in Liver Transplant Recipients
The purpose of this research study is to investigate whether or not oral maribavir is safe and effective compared to oral ganciclovir for preventing CMV disease when administered for up to 14 weeks in patients who have had a…
- Trial name
- NCT00497796
- Testing
- maribavir, ganciclovir
- Where
- 55 sites in United States
- Volunteers
- 307 people
- Sponsor
- Shire
Cytomegalovirus Prophylaxis
A Clinical Study of Letermovir (MK-8228) in Children and Adolescents Who Receive a Kidney Transplant (KT) (MK-8228-077)
Researchers are looking for a way to prevent cytomegalovirus (CMV) in children and adolescents who receive a kidney transplant (KT) and weigh less than 40 kilograms (88.2 pounds).
- Trial name
- NCT07199465
- Testing
- Letermovir
- Where
- 21 sites in United States
- Volunteers
- 40 people
- Sponsor
- Merck Sharp & Dohme LLC
Cytomegalovirus Disease, Kidney Transplant Infection
A Phase 3 Study of Brincidofovir Versus Valganciclovir for the Prevention of Cytomegalovirus
This was a randomized, double-blind, double-dummy, parallel-group, multicenter study of the efficacy, safety, and tolerability of oral brincidofovir (BCV) versus valganciclovir for the prevention of cytomegalovirus (CMV) disease…
- Trial name
- NCT02439957
- Testing
- Brincidofovir, Valganciclovir
- Where
- 3 sites in United States
- Volunteers
- 6 people
- Sponsor
- Jazz Pharmaceuticals
Cytomegalovirus Infections, Cytomegalovirus Viremia
HCMV Breakthrough Infections During Letermovir Prophylaxis
The goal of this clinical trial is to compare two strategies to monitor human cytomegalovirus (HCMV) infections in transplanted patients receiving letermovir (LTV) as anti-HCMV prophylaxis.
- Conditions
- Cytomegalovirus Infections, Cytomegalovirus Viremia, Hematopoietic Stem Cell Transplantation
- Trial name
- CMVbreak (NCT06339892)
- Testing
- Determination of HCMV DNA in plasma after DNAse digestion., Determination of HCMV DNA in blood or plasma.
- Where
- 8 sites in Italy
- Volunteers
- 140 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Cytomegalovirus Infections
Cytomegalovirus (CMV) Viremia and Disease Occurrence in Pediatric Allogeneic Stem Cell Transplantation Recipients
The primary objective is to determine the incidence of CMV viremia and disease in pediatric allogeneic stem cell transplantation recipients who received ganciclovir prophylaxis up until day +100 by retrospective analysis.
- Trial name
- NCT04478474
- Testing
- Ganciclovir
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- New York Medical College
CMV Infection
Preemptive Therapy With CMV-specific T Cells Infusion to Prevent Refractory CMV Infection Post Transplantation
Cytomegalovirus (CMV) infections remain an important cause of morbidity and mortality in allogeneic hematopoietic cell transplant (HSCT) recipients, especially in patients received haploidentical transplantation.
- Trial name
- NCT02985775
- Testing
- Donor-derived CMVpp65-specific T cells
- Where
- China
- Volunteers
- 41 people
- Sponsor
- Peking University People's Hospital
Cytomegalovirus Infections, HIV Infections
A Randomized, Double-Blind Study of the Efficacy and Safety of Oral Ganciclovir for the Prevention of CMV Disease in People Infected With the Human Immunodeficiency Virus
To evaluate the efficacy of oral ganciclovir in preventing progression to cytomegalovirus (CMV) disease (e.g., CMV retinitis, gastrointestinal CMV disease) in CMV-infected people with HIV infection and CD4 lymphocyte counts <=…
- Trial name
- NCT00002095
- Testing
- Ganciclovir
- Where
- 19 sites in United States
- Volunteers
- 700 people
- Sponsor
- Hoffmann-La Roche